State of Wisconsin Investment Board bought a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 31,000 shares of the biopharmaceutical company’s stock, valued at approximately $510,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LXRX. Teachers Advisors LLC increased its position in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock valued at $1,478,000 after acquiring an additional 27,378 shares during the period. DUPONT CAPITAL MANAGEMENT Corp acquired a new position in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $519,000. Bank of New York Mellon Corp increased its position in shares of Lexicon Pharmaceuticals by 7.3% in the 1st quarter. Bank of New York Mellon Corp now owns 280,253 shares of the biopharmaceutical company’s stock valued at $4,018,000 after acquiring an additional 19,176 shares during the period. Pictet Asset Management Ltd. increased its position in shares of Lexicon Pharmaceuticals by 12.4% in the 1st quarter. Pictet Asset Management Ltd. now owns 61,550 shares of the biopharmaceutical company’s stock valued at $883,000 after acquiring an additional 6,800 shares during the period. Finally, Virginia Retirement Systems ET AL increased its position in shares of Lexicon Pharmaceuticals by 120.5% in the 1st quarter. Virginia Retirement Systems ET AL now owns 88,200 shares of the biopharmaceutical company’s stock valued at $1,265,000 after acquiring an additional 48,200 shares during the period.
Several research firms recently issued reports on LXRX. BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th. Wedbush reaffirmed an “ourperform” rating and set a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $27.00.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) opened at 14.74 on Wednesday. Lexicon Pharmaceuticals, Inc. has a 12 month low of $13.41 and a 12 month high of $19.62. The firm’s 50-day moving average price is $15.02 and its 200 day moving average price is $15.39. The firm’s market capitalization is $1.56 billion.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $18.34 million. During the same period in the previous year, the business posted ($0.37) earnings per share. The business’s revenue was down 40.3% compared to the same quarter last year. Analysts anticipate that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/09/13/state-of-wisconsin-investment-board-invests-510000-in-lexicon-pharmaceuticals-inc-lxrx.html.
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.